04:08 AM EDT, 09/13/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said late Thursday the US Food and Drug Administration approved Swiss healthcare company Roche's cancer immunotherapy, Tecentriq Hybreza, in combination with Halozyme's Enhanze drug delivery technology.

The product is a combination of the atezolizumab antibody and Halozyme's human hyaluronidase enzyme, rHuPH20.

The product will be available in the US for adults with certain types of lung, liver, skin and soft tissue cancer.

Price: 60.00, Change: -0.54, Percent Change: -0.89